MEKINIST – trametinib 0.5 mg and 2 mg tablet

Novartis Pharmaceuticals Corp

malignant solid tumor with BRAF V600E mutation; non-small cell lung cancer with BRAF V600E mutation; malignant melanoma with BRAF V600K mutation; anaplastic thyroid carcinoma with BRAF V600E mutation; malignant melanoma with BRAF V600E mutation; low grade glioma with BRAF V600E mutation; malignancy

Controlled Room Temp (20-25°C)